Prediabetes Market Size, Share & Trends Report

Prediabetes Market Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones), By Age Group (Children, Adult), By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-4-68040-221-4
  • Number of Report Pages: 134
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2022
  • Forecast Period: 2024 - 2030 
  • Industry: Healthcare

Market Segmentation

  • Prediabetes Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
    • Diguanide
    • Thiazolidinediones
    • Glucagon-like peptide-1 agonists (GLP-1)
    • SGLT2 inhibitors
    • DPP-4 inhibitors
    • Others
  • Prediabetes Age group Outlook (Revenue, USD Million, 2018 - 2030)
    • Children (12-18 years)
    • Adults (18-49)
    • Elderly (50+)
  • Prediabetes Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America Prediabetes Market, by Drug Class
        • Diguanide
        • Thiazolidinediones
        • Glucagon-like peptide-1 agonists (GLP-1)
        • SGLT2 inhibitors
        • DPP-4 inhibitors
        • Others
      • North America Prediabetes Market, by Age group
        • Children (12-18 years)
        • Adults (18-49)
        • Elderly (50+)
      • U.S.
        • U.S. Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • U.S. Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Canada
        • Canada Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Canada Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
    • Europe
      • Europe Prediabetes Market, by Drug Class
        • Diguanide
        • Thiazolidinediones
        • Glucagon-like peptide-1 agonists (GLP-1)
        • SGLT2 inhibitors
        • DPP-4 inhibitors
        • Others
      • Europe Prediabetes Market, by Age group
        • Children (12-18 years)
        • Adults (18-49)
        • Elderly (50+)
      • UK
        • UK Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • UK Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Germany
        • Germany Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Germany Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • France
        • France Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • France Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Italy
        • Italy Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Italy Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Spain
        • Spain Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Spain Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Denmark
        • Denmark Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Denmark Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Sweden
        • Sweden Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Sweden Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Norway
        • Norway Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Norway Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
    • Asia Pacific
      • Asia Pacific Prediabetes Market, by Drug Class
        • Diguanide
        • Thiazolidinediones
        • Glucagon-like peptide-1 agonists (GLP-1)
        • SGLT2 inhibitors
        • DPP-4 inhibitors
        • Others
      • Asia Pacific Prediabetes Market, by Age group
        • Children (12-18 years)
        • Adults (18-49)
        • Elderly (50+)
      • Japan
        • Japan Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Japan Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • China
        • China Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • China Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • India
        • India Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • India Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Australia
        • Australia Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Australia Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • South Korea
        • South Korea Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • South Korea Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Thailand
        • Thailand Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Thailand Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
    • Latin America
      • Latin America Prediabetes Market, by Drug Class
        • Diguanide
        • Thiazolidinediones
        • Glucagon-like peptide-1 agonists (GLP-1)
        • SGLT2 inhibitors
        • DPP-4 inhibitors
        • Others
      • Latin America Prediabetes Market, by Age group
        • Children (12-18 years)
        • Adults (18-49)
        • Elderly (50+)
      • Brazil
        • Brazil Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Brazil Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Mexico
        • Mexico Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Mexico Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Argentina
        • Argentina Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Argentina Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
    • MEA
      • MEA Prediabetes Market, by Drug Class
        • Diguanide
        • Thiazolidinediones
        • Glucagon-like peptide-1 agonists (GLP-1)
        • SGLT2 inhibitors
        • DPP-4 inhibitors
        • Others
      • MEA Prediabetes Market, by Age group
        • Children (12-18 years)
        • Adults (18-49)
        • Elderly (50+)
      • South Africa
        • South Africa Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • South Africa Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Saudi Arabia
        • Saudi Arabia Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Saudi Arabia Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • UAE
        • UAE Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • UAE Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)
      • Kuwait
        • Kuwait Prediabetes Market, by Drug Class
          • Diguanide
          • Thiazolidinediones
          • Glucagon-like peptide-1 agonists (GLP-1)
          • SGLT2 inhibitors
          • DPP-4 inhibitors
          • Others
        • Kuwait Prediabetes Market, by Age group
          • Children (12-18 years)
          • Adults (18-49)
          • Elderly (50+)

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2018 to 2030
  • Market estimates and forecast for product segments up to 2030
  • Regional market size and forecast for product segments up to 2030
  • Market estimates and forecast for application segments up to 2030
  • Regional market size and forecast for application segments up to 2030
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon